title: Iron status and HFE genotype in erythrocyte pyruvate kinase deficiency: study of Italian cases.
abstract: We evaluated the iron status and searched for mutations C282Y and H63D in the hereditary hemochromatosis gene (HFE) in 34 pyruvate kinase (PK)-deficient patients from 29 unrelated families. Nine had received multiple transfusions. Thirteen of the 25 nontransfused patients displayed increased serum ferritin concentration, in the absence of conditions known to raise this parameter. HFE genotype was abnormal in 9 of 34 patients. The allele frequency was 1.8% for mutation 845G--> (C282Y) and 16.1% for mutation 187C-->G (H63D). Nontransfused subjects with abnormal genotype had serum ferritin and transferrin saturation values significantly higher than those with wild-type genotype. Of the 12 adult nontransfused patients with increased iron status parameters, 1 was C282Y homozygous, 1 compound heterozygous for C282Y and H63D, 3 H63D heterozygous, and 7 had a normal HFE genotype. Serum ferritin and transferrin saturation were not related to hemoglobin, reticulocytes, and bilirubin concentration. At multivariate analysis serum ferritin was independently associated with age and gender, but not with splenectomy and HFE genotypes. The retrospective evaluation of the iron status profile of 10 patients (3 with abnormal and 7 with wild-type HFE genotype) with at least 10 years follow-up showed that overt iron accumulation requiring iron chelation had occurred only in the 3 patients (2 of whom were splenectomized) with the mutated HFE gene.
authors.affiliation: Divisione di Ematologia, IRCCS Ospedale Maggiore, Via F. Sforza 35, 20122 Milan, Italy. div_emat@polic.cilea.it
authors.forename: A
authors.initials: A
authors.lastname: Zanella
authors.forename: P
authors.initials: P
authors.lastname: Bianchi
authors.forename: A
authors.initials: A
authors.lastname: Iurlo
authors.forename: C
authors.initials: C
authors.lastname: Boschetti
authors.forename: E
authors.initials: E
authors.lastname: Taioli
authors.forename: C
authors.initials: C
authors.lastname: Vercellati
authors.forename: M
authors.initials: M
authors.lastname: Zappa
authors.forename: E
authors.initials: E
authors.lastname: Fermo
authors.forename: D
authors.initials: D
authors.lastname: Tavazzi
authors.forename: M
authors.initials: M
authors.lastname: Sampietro
mesh_terms: D000293:Adolescent; D000328:Adult; D000743:Anemia, Hemolytic / Q000097:blood / Q000235:genetics* / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004252:DNA Mutational Analysis; D004912:Erythrocytes / Q000201:enzymology*; D005260:Female; D005293:Ferritins / Q000097:blood; D005838:Genotype; D006680:HLA Antigens / Q000235:genetics*; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I / Q000235:genetics*; D006801:Humans; D007223:Infant; D019190:Iron Overload / Q000097:blood / Q000453:epidemiology / Q000209:etiology*; D007558:Italy / Q000453:epidemiology; D008297:Male; D008565:Membrane Proteins; D011770:Pyruvate Kinase / Q000097:blood / Q000172:deficiency*; D013156:Splenectomy / Q000009:adverse effects; D014168:Transferrin / Q000378:metabolism
chemical_list: C103673:HFE protein, human; D006680:HLA Antigens; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I; D008565:Membrane Proteins; D014168:Transferrin; D005293:Ferritins; D011770:Pyruvate Kinase